Invests in
Locations:
Min Investment:
$50,000.00Max Investment:
$150,000,000.00Target Investment:
$25,000,000.00
Skills
Education
Lists including Carol
Work Experience
2018
Partner
2021
Board Member: Orbital Therapeutics, Human Immunology Biosciences (acquired) Board Observer: Kisbee Therapeutics (2021-Present), Remix Therapeutics (2021-Present), Resonance Medicine (2021-2023), Sesh Therapy (2021-2023), Locana Bio (2020-2024), CERo Therapeutics (2020-2022), Metacrine (2019-2020),
Principal
2019 - 2021
Senior Associate
2018 - 2019
Consultant/Intern
2018 - 2018
2019
Co-Founder and Chief Operating Officer
2023
Co-Founder and SVP, Strategy
2022 - 2023
Co-founder and VP, Business Development
2019 - 2021
2022
Co-founder, Board Member
2022
2021
Board Member
2021
Board Member of Metrodora Foundation
2021
2019 - 2019
Associate Director of Corporate Development
2019 - 2019
ARCH Venture Partners company build
2016 - 2017
Business Development and Corporate Strategy Associate; Launch Fellow
2016 - 2017
Business Development and Corporate Strategy Associate (Jun 2017-Sept 2017) Launch Fellow (May 2016-Aug 2016): Helped prepare Magenta Therapeutics for launch and $48.5M Series A, working with Third Rock Ventures and Atlas Venture.
2015 - 2016
Senior Associate Consultant
2015 - 2016
Senior Associate Consultant (2016) Associate Consultant (2015)
2014 - 2014
R&D Strategy; Innovation Fellow
2014 - 2014
The Regenerative Medicine Discovery Performance Unit built a portfolio of innovative stem cell and regenerative medicines through in-house R&D, strategic alliances, and in-licensing opportunities.